menu search

CRL / Charles River: Strong Earnings Manifest Life Science Megatrends

Charles River: Strong Earnings Manifest Life Science Megatrends
In the past year, Charles River (-13.59%) has trailed both the S&P 500 (+4.83%) in addition to the healthcare index, IXHC (+21.81%). This reflects a -44.57% YoY free cash flow decline owing to material reductions in net income from 2021-22. Read More
Posted: May 11 2023, 23:09
Author Name: Seeking Alpha
Views: 111573

CRL News  

Consulting firm Charles River raises dividend to boost yield above the S&P 500's, while profit and revenue miss expectations

By Market Watch
November 2, 2023

Consulting firm Charles River raises dividend to boost yield above the S&P 500's, while profit and revenue miss expectations

CRA International Inc. CRAI, +0.09%, the consulting firm also known as Charles River Associates, said Thursday that it raised its quarterly dividend, more_horizontal

Charles River (CRL) to Report Q3 Earnings: What's in Store?

By Zacks Investment Research
November 1, 2023

Charles River (CRL) to Report Q3 Earnings: What's in Store?

Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the more_horizontal

Why Charles River (CRL) Could Beat Earnings Estimates Again

By Zacks Investment Research
October 24, 2023

Why Charles River (CRL) Could Beat Earnings Estimates Again

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely more_horizontal

Here's Why You Should Retain Charles River (CRL) Stock Now

By Zacks Investment Research
October 10, 2023

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance. more_horizontal

Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar

By InvestorPlace
October 5, 2023

Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar

Stocks ended the third quarter on a sour note. The Federal Reserve's aggressive posture against inflation combined with soaring interest rates have in more_horizontal

Charles River (CRL) Launches LVV-based Gene Therapy Platform

By Zacks Investment Research
October 2, 2023

Charles River (CRL) Launches LVV-based Gene Therapy Platform

Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market. more_horizontal

Charles River (CRL) Opens a RightSource Lab in Stevenage

By Zacks Investment Research
September 26, 2023

Charles River (CRL) Opens a RightSource Lab in Stevenage

Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster. more_horizontal

Charles River (CRL) Announces Partnership With Related Sciences

By Zacks Investment Research
September 15, 2023

Charles River (CRL) Announces Partnership With Related Sciences

Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica. more_horizontal


Search within

Pages Search Results: